Abstract:For advanced stage ovarian cancer, surgery to perform maximal tumor cytoreduction has been the mainstay of initial therapy. 1 The extent of residual disease at the completion of surgery is highly prognostic, with lower-volume residual disease associated with improved survival. 2 Prior studies examining the association between cytoreductive effort and survival have included mainly high-grade and serous ovarian tumors, the most common histologic subtype of ovarian cancer. 2 The prognostic significance of cytoreductive status in less-common histologic types has been relatively understudied. Given the distinct clinical and biological differences across histologic subtypes in epithelial ovarian cancer, 3 ,4 data derived mainly from common high-grade serous tumors may not apply to less-common histologic types. The objective of this study was to examine the association between primary cytoreduction status and survival for patients with less-common, advanced-stage epithelial ovarian carcinoma. This cohort study was deemed exempt by the Columbia University institutional review board with a waiver of informed consent because it included only publicly available, deidentified data. This study is reported following the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline. The study population included patients with stage III epithelial ovarian carcinomas who underwent primary cytoreductive surgery from 2011 to 2020, with data collected from the National Cancer Database. 5 The association of residual disease at the completion of primary cytoreduction (complete cytoreduction [R0], optimal cytoreduction [R1], and suboptimal cytoreduction [R2]) and overall survival (OS) were assessed with Cox proportional hazards regression models, adjusting for other clinical and demographic characteristics. P values were 2-tailed, and statistical significance was set at P < .05. Analyses were conducted using SAS software version 9.4 (SAS Institute). Further details are provided in the eMethods in Supplement 1. Analyses were conducted from October 2023 to February 2024. A total of 1100 patients with ovarian clear cell carcinoma (CCC), 495 patients with mucinous ovarian carcinoma (MOC), 1103 patients with low-grade serous ovarian carcinoma (LGSOC), and 13 046 patients with high-grade serous ovarian carcinoma (HGSOC) were examined for analysis. Complete cytoreduction rates were overall higher in less-common cancer types compared with HGSOC (73.2% for LGSOC, 74.0% for CCC, 72.1% for MOC, and 59.9% for HGSOC; P < .001). Complete cytoreduction rates increased during the study period in HGSOC (52.2% to 62.8%; relative increase, 27.8%; P < .001), but not in less-common cancers (CCC, 60.5% to 77.3%; P = .32; MOC, 60.0% to 70.7%; P = .18; LGSOC, 67.0% to 70.1%; P = .48) (Figure, A). Across the 4 histologic types, the annual number of primary cytoreductive surgical procedures decreased by 41.6% from 2011 to 2020 (1811 to 1057 procedures) (Figure, A). In the HGSOC cohort, larger residual disease after primary cytoreduction was associated with decreased OS (5-year rates: R0, 58.5%; R1, 45.0%; R2, 36.2%; R1 vs R0 adjusted hazard ratio [aHR], 1.44; 95% CI, 1.36-1.52; R2 vs R0 aHR, 1.77; 95% CI, 1.63-1.93) (Table). Results remained consistent in stage IIIC disease (Figure, B). In the CCC and MOC cohorts, complete cytoreduction was associated with improved OS (5-year rates for CCC: R0, 45.2%; R1, 25.9% R2, 29.5%; R1 vs R0 aHR, 1.72; 95% CI, 1.42-2.08; R2 vs R0 aHR, 1.95; 95% CI, 1.35-2.81). Five-year OS rates for MOC were 40.5% for R0, 25.1% for R1 (R1 vs R0 aHR, 1.55; 95% CI, 1.17-2.07), and 26.3% for R2 (R2 vs R0 aHR, 1.63; 95% CI, 1.03-2.56) (Table). These survival associations remained in stage IIIC disease (Figure, C and D; Table). For the LGSOC cohort, the association between the extent of cytoreduction and OS was not statistically significant. Five-year OS rates were 80.8% for R0, 75.3% for R1 (R1 vs R0 aHR, 1.04; 95% CI, 0.75-1.45), and 63.0% for R2 (R2 vs R0 aHR, 1.19; 95% CI, 0.66-2.12) (Table). The finding was similar in stage IIIC disease (Figure, E), with 5-year OS rates of 76.6% for R0, 75.4% for R1 (R1 vs R0 aHR, 1.08; 95% CI, 0.75-1.54), and 66.0% for R2 (R2 vs R0 aHR, 1.06; 95% CI, 0.56-1.98) (Table). This cohort study found that the association of residual tumor volume at primary cytoreduction with survival was less robust in LGSOC compared with other histology types. The decreasing use of primary cytoreductive surgery likely reflects an increasing use of neoadjuvant chemotherapy for advanced-stage ovarian cancer. The increase in use of neoadjuvant chemotherapy has also been demonstrated for LGSOC. 6 However, neoadjuvant chemotherapy is associated with decreased survival for advanced-stage LGSOC compared with primary c -Abstract Truncated-

Low-Grade Serous Ovarian Cancer: Expert Consensus Report on the State of the Science

Abstract 6065: Patterns of Dysregulated Coding and Noncoding Gene Expression in High-Grade Serous Ovarian Carcinomas

Targeted Therapies in Low-Grade Serous Ovarian Cancers

Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy

Advances in precision therapy of low-grade serous ovarian cancer: A review

Current concept of low-grade serous ovarian carcinoma

High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints

Abstract 1562: Germline Polymorphisms in Cancer Stem Cell Genes Associate with Survival among Women with High-Grade Serous Ovarian Cancer

Novel Targeted Agents in Advanced and Recurrent Low-Grade Serous Ovarian Cancer: A Silver Lining in the Therapy of a Chemoresistant Disease?

Prognostic And Therapeutic Factors For Low-Grade Serous Ovarian Carcinoma: A Multicentric, Retrospective Study Of The Turkish Society Of Gynaecologic Oncology

Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.

Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma: an international multicentre analysis

High-throughput drug screening identifies novel therapeutics for Low Grade Serous Ovarian Carcinoma

Exploring novel approaches in the systemic therapy of low-grade serous carcinoma of the ovary: a literature review

Changes in the tumour microenvironment mark the transition from serous borderline tumour to low-grade serous carcinoma

Early Stage Primary Ovarian Mucinous Carcinoma: Outcome-based Clinicopathological Study in Comparison with Serous Carcinoma.

Quantitative Proteomics Identifies Conserved Proteins and Altered Regulation of Mucin-16 in Low Grade Serous Ovarian Cancers

Abstract A107: Characterizing the genomic and immunologic landscape of serous borderline tumors and low-grade serous ovarian cancer

Deep Quantitative Proteomics Identifies Conserved Proteome Alterations in Low and High-Grade Serous Ovarian Cancers

NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022.

Primary Cytoreduction and Survival for Patients With Less-Common Epithelial Ovarian Cancer